• Home
  • COVID-19 Related Codes (UB-04 Billing)

COVID-19 Related Codes (UB-04 Billing)

Blue Cross and Blue Shield of Kansas (BCBSKS) continues to monitor COVID-19 and the changes with billing new codes. The following new codes will be reimbursed as follows:

HCPCS Code

Nomenclature

MAP'd like:

Effective Date

Q0240

Injection, casirivimab and imdevimab, 600 mg

Q0245

02/01/2022

Q0244

Injection, casirivimab and imdevimab, 1200 mg

Q0245

02/01/2022

Q0220

Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg

Q0245

02/01/2022

M0240

Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses

M0243

02/01/2022

M0244

Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the covid-19 public health emergency

 

M0241

02/01/2022

M0246

Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the covid-19 public health emergency

 

M0241

02/01/2022

M0248

Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the covid-19 public health emergency

 

M0241

02/01/2022

M0220

Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring

M0241

02/01/2022

M0221

Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the covid-19 public health emergency

M0241

02/01/2022

0051A

Pfizer-BioNTech Covid-19 Vaccine Pre-Diluted (Gray Cap) Administration - First dose

0013A

02/01/2022

0052A

Pfizer-BioNTech Covid-19 Vaccine Pre-Diluted (Gray Cap) Administration - Second dose

 

0013A

02/01/2022

0053A

Pfizer-BioNTech Covid-19 Vaccine Pre-Diluted (Gray Cap) Administration - Third dose

0013A

02/01/2022

0054A

Pfizer-BioNTech Covid-19 Vaccine Pre-Diluted (Gray Cap) Administration – Booster

0013A

02/01/2022

0071A

Pfizer-BioNTech Covid-19 Pediatric Vaccine (Orange Cap) - Administration - First dose

0013A

02/01/2022

0072A

Pfizer-BioNTech Covid-19 Pediatric Vaccine (Orange Cap) - Administration - Second dose

0013A

02/01/2022

0073A

Pfizer-BioNTech Covid-19 Pediatric Vaccine (Orange Cap) - Administration - Third dose

0013A

02/01/2022

91305

Pfizer-BioNTech Covid-19 Vaccine Pre-Diluted (Gray Cap)

 

91306

02/01/2022

91307

Pfizer-BioNTech Covid-19 Pediatric Vaccine (Orange Cap)

91306

02/01/2022

 

If you have any questions regarding this newsletter, please contact your BCBSKS Institutional Relations provider consultant.